This website is intended for healthcare professionals only.
Take a look at a selection of our recent media coverage:
24th July 2024
Improving working conditions and introducing incentives in four key areas have been suggested as ways to retain healthcare professionals in hospitals, according to the EU-funded METEOR Project.
Published in the journal Qualitative Health Research, the findings highlight professional and personal support, education, financial incentives and regulatory measures as the main factors that healthcare organisations should focus on to retain their staff, in addition to improving working conditions.
The study involved a series of eight online co-creation workshops and four Delphi sessions surveying nurses and clinicians at eight European hospitals in four countries: Belgium, the Netherlands, Italy and Poland.
A thematic analysis was conducted, resulting in multiple interventions that were clustered into the four pre-defined themes.
Interviewees in all four countries emphasised the importance of leadership training, interdisciplinary teamwork and support for the non-clinical workload as key factors that could improve their working conditions.
Anke Boone, a researcher at the Centre for Environment and Health at KU Leuven and a co-author of the METEOR study, said: ‘In our workshops, healthcare professionals told us that personal support is key to enhancing job satisfaction. It also creates resilience against workplace stressors, mainly by knitting teams together more strongly.’
The professional and personal support interventions highlighted in the study to retain staff included regular interprofessional team meetings, leadership training programs, self-scheduling and sabbaticals, support for administrative and non-clinical work, and the provision of psychological counselling.
When it came to education, interviewees from all countries stressed the need for continuous professional development opportunities, including onboarding and mentorship programmes. They also advocated for a hospital-based development budget, allocated to each employee, as part of a comprehensive personal development plan.
Financial incentives included the provision of competitive salaries, adequate spending on infrastructure, extra benefits such as secure, permanent employment contracts.
However, as Olivia Lavreysen, a researcher at the Centre for Environment and Health at KU Leuven and a co-author of the METEOR study, pointed out, ‘many healthcare professionals say they’re willing to take a pay cut if it would mean an improvement in their current working conditions. That clearly shows that job quality and the level of support from healthcare organisations is more important than money.’
Desired regulatory measures addressed the need for harmonised legislation spanning local, national and international levels, fixed healthcare worker-to-patient ratios, and effective workload monitoring tools.
Interviewees hoped that such measures would alleviate workload pressures, support retention and ensure sustainable staffing levels, which are crucial for mitigating burnout and fostering professional satisfaction.
The authors concluded that while there is no one-size-fits-all approach to workforce retention, tailoring these interventions to address pressures within an organisation is encouraged.
Co-author Lode Godderis, professor at the Centre for Environment and Health at KU Leuven, added: ‘Healthcare providers need to look closely into their organisations and listen to employees to address their needs.’
Earlier METEOR findings revealed that 9% of doctors and nearly 14% of nurses intend to leave their professions, citing low job satisfaction, growing depersonalisation and emotional exhaustion as primary factors.
4th July 2024
The results of a national audit and quality improvement project looking to optimise cardiovascular care across Italy has recently been presented at the Italian National Association of Hospital Cardiologists conference. Here, Professor Furio Colivicchi speaks to Helen Quinn about the rationale for the audit study, the key findings and next steps, plus the team’s ambitions to widen the scope of the project to support more patients nationally and across Europe.
Cardiovascular diseases (CVDs) are the leading cause of death globally. Figures produced by the World Health Organization (WHO) estimate 17.9 million lives are lost each year as a result of CVDs, with four out of five of these deaths being a result of heart attacks and strokes.
Finding ways to reduce death and ill health related to CVD is a primary goal of many researchers around the globe, including Professor Furio Colivicchi.
After training in internal medicine, Professor Colivicchi moved to clinical cardiology and developed a particular interest in secondary cardiovascular prevention. He joined the San Filippo Neri Hospital in Rome in 1991, becoming its director of cardiology in 2013, and he’s also a professor of cardiovascular medicine at Tor Vergata University of Rome’s School of Medicine.
In Italy, the prevalence of CVD is nearly two-fold higher than the global rate, and Professor Colivicchi is working hard to improve best practice and patient outcomes. He is currently undertaking an audit of cardiovascular care across the country with the Italian National Association of Hospital Cardiologists (ANMCO) for which he is also immediate past president.
The audit analyses admissions and treatment pathways for CVD patients throughout the country and examines whether the guidelines for treatments are being adhered to and how to improve this likelihood.
Current guidelines from the European Society of Cardiology (ESC), published in 2019, advise the use of high-intensity statins and subsequently, ezetimibe and PCSK9 inhibitors to reduce low-density lipoprotein cholesterol (LDL-C) levels below 55 mg/dL within four weeks.
However, such combination therapy is not used as much as it should be in clinical practice, and Professor Colivicchi and his team suggest this is due to therapeutic inertia, where clinicians do not always consider the information contained in such guidelines.
‘There is a gap between what should be done according to the guidelines, what the scientific evidence is about the management of certain cardiovascular conditions and what is actually performed in clinical practice,’ Professor Colivicchi says.
According to the guidelines patients with recurrent cardiac events should be reaching lower LDL-C levels of 40mg/dL – a target Professor Colivicchi describes as ‘rather ambitious’.
‘We have evidence from several observational studies in Europe, the United States and Italy that these levels were not reached in clinical practice. Patients were not following a proper path to the reduction of cardiovascular risk, which is the reduction of ischemic recurrences in particular,’ he explains. ‘Our idea was to have a photo of what was going on and then give feedback to the institutions involved in the project.’
To begin the study, entitled ‘Optimisation of the pathways from hospital discharge to follow up: the APPRO-EVO AUDIT ACS Project’, Professor Colivicchi organised observations in over 50 hospitals throughout Italy, which involved around 500 cardiologists and more than 1,100 patients.
The clinicians involved in the study collected data over four weeks, describing the general management of their patients, the epidemiological features of this population, the kind of lipid-lowering treatment implemented and whether these patients could or could not reach the recommended targets as outlined in the ESC guidelines. The audit and feedback methodology aimed to improve the quality of healthcare given to high-risk patients.
Professor Colivicchi says: ‘This is the general idea about audit; it is a circle in which you have to check what you do, try to improve your practice, and then check again to see what has actually happened. If you close the gap, then there is always an improvement.’
After collecting and analysing the initial data, the researchers undertook a second audit involving more than 1,000 additional patients to see if anything had changed following the feedback from the first audit.
Professor Colivicchi found a ‘striking increase’ in the use of new drugs in the second audit, particularly PCSK9 inhibitors and monoclonal antibodies, to treat the most severe forms of hypercholesterolemia.
The results, which Professor Colivicchi presented at the recent ANMCO conference, show that in the first phase, just 60% of the patients were discharged from hospital with a combination therapy, including a statin plus ezetimibe. The remaining patients were discharged usually with only a statin.
Following the feedback from the first audit, the number of patients receiving combination therapy rose to 75%, and the use of PCSK9 inhibitors rose from 10% to 17% in the second audit. In addition, more than 80% of patients reached the recommended targets in the guidelines.
‘We were able to demonstrate that when there is a particular attention to clinical practice, the healthcare providers tend to improve their performance. Patients were followed more carefully because when you know that someone is observing you and assessing what you’re doing, there is specific care in what is actually done,’ says Professor Colivicchi.
The next stage is to expand the project from 50 to 200 and then 300 hospitals, including minor and community hospitals throughout Italy. Professor Colivicchi hopes that clinicians will perform the assessments every six months.
He adds: ‘When you implement a quality improvement procedure within every single hospital, you can improve the practice and reach the goals recommended by the guidelines. If you reach the target, you can expect to improve clinical outcomes over the medium to long term. So, this is the underlying logic: you need that feedback.’
Through the study, Professor Colivicchi notes that the CVD patients arriving at the hospital often showed many modifiable risk factors that had not been addressed. These included smoking, being diabetic with suboptimal control of glucose metabolism, hypertension without proper treatment, as well as high cholesterol. The findings from the study show that if antiplatelet therapy is appropriately managed to reduce LDL-C, cardiovascular recurrence events will also be reduced – even in high-risk populations.
‘Prevention is relevant. Secondary prevention is extremely relevant because the effectiveness of preventive procedures is more prevalent in those patients at high cardiac risk. So, you can reduce the number of the events that are recurrent in more than 50% of patients,’ Professor Colivicchi explains.
The team is sharing the data with the Italian Ministry of Health and the local health authorities to provide them with evidence that certain interventions are effective in improving clinical practice. The evidence from the audit allows clinicians to optimise the choice of treatments, ultimately promoting a higher quality of care in a safer and more efficient way.
Professor Colivicchi’s evidence showed that, overall, there was a better use of therapeutic resources in the at-risk population and thus an increased likelihood of achieving the therapeutic targets recommended by the current ESC guidelines.
‘This experience is just one step in the direction of quality improvement. We think we are always doing the best for our patients, but this is not necessarily true. We have to measure what we do every day, and then we must be accountable for what we do. This is an approach we can implement to have some objective evidence of our clinical practice and to improve it properly,’ Professor Colivicchi concludes.
Only time will tell just how extensive the improvements are to patient care throughout Italy as a result of the audit study, but the researchers hope the impact is even more widespread than that. Their process is likely to be applicable to other health services and can help to support the implementation of best practice around the world.
23rd May 2024
Adopting a risk-stratified approach to breast cancer screening could help improve the benefit-to-harm ratio and the cost-effectiveness of screening programmes, European experts say.
In an invited review published in the journal European Radiology outlining the European Society of Breast Imaging’s general recommendations on breast cancer screening, the authors said that programmes usually included all women irrespective of their breast cancer risk, with age being the only determining factor.
Senior author Dr Ritse Mann, breast and interventional radiologist at the Radboud University Medical Center in Nijmegen, The Netherlands, and colleagues said breast cancer was the most frequently occurring cancer in Europe, accounting for about 15% of all new cancer cases and for about 30% of all new cancer cases in women.
Mammographic screening allowed for early cancer diagnosis, thereby reducing cancer mortality and the need for aggressive treatments.
‘Nevertheless, breast cancer remains the leading cause of cancer death among women worldwide, and although the benefits of mammographic screening outweigh the harms in the general population and the “one-size-fits-all” approach remains easier to implement, further improvements are sought,’ Dr Mann and colleagues wrote.
‘Moving to screening programmes adjusted to personal risk level instead of age-based population screening could improve the performance of a screening programme by reducing underdiagnosis, false positives, and over-diagnosis as well as improving cost-effectiveness.’
Several risk prediction models were available to estimate an individual’s risk of developing breast cancer, they said.
If possible, risk assessment should be performed at a young age (approximately 25 years) to effectively tailor screening recommendations.
Women found to be at a high risk of developing breast cancer should start screening as early as 25 years of age with annual breast MRI (evidence level 1), the recommendations stated, supplemented with annual or biennial mammography from age 35-40 years.
Evidence also supported the use of breast MRI screening in women with extremely dense breast tissue, preferably every two to three years.
‘If MRI is not available, supplemental ultrasound can be performed as an alternative, although the added value of supplemental ultrasound regarding cancer detection remains more limited,’ the experts wrote.
Breast density category should always be reported after mammography screening, they noted, as this had important implications for the performance of supplemental and alternative imaging methods.
Overall, regular mammography should be considered the mainstay of breast cancer screening (evidence level 1), but digital breast tomosynthesis could be performed as an alternative.
For women at intermediate risk of breast cancer, supplemental imaging modalities, including digital breast tomosynthesis, ultrasound, breast MRI, and, more recently, contrast-enhanced mammography, were available and had already shown potential to further increase diagnostic performance.
Artificial intelligence had also shown promising results in supporting risk categorisation and interval cancer reduction, Dr Mann and colleagues noted.
Women should be properly informed about the advantages as well as disadvantages of a breast cancer screening test to be able to make informed choices. Indeed, the experts said: ‘Individual screening recommendations should be made through a shared decision-making process between women and physicians.’
If there was a move to risk-based cancer screening rather than relying on age-based population screening, informed decision-making would become even more important to increase acceptability among those lower risk women who were candidates for reduced screening intensity, Dr Mann and colleagues suggested.
13th March 2024
Almost one in 10 doctors across the European Union (EU) intend to leave their profession, according to a new cross-sectional study from the EU-funded METEOR Project, highlighting widespread retention issues.
Researchers from the METEOR Project – which collects scientific knowledge on job retention of healthcare workers in Europe to develop policy recommendations to increase job retention – asked 381 physicians and 1,351 nurses at hospitals in Belgium, the Netherlands, Italy and Poland about their intention to exit the profession or leave their current hospital, and the factors influencing their decisions to quit.
The results showed 9% of doctors and nearly 14% of nurses declaring an intention to leave their profession, citing low job satisfaction, growing depersonalisation and emotional exhaustion as the primary factors.
The survey also revealed 16.3% of doctors and 8.4% of nurses are considering leaving their current jobs. Factors impacting nurse and physician retention in hospitals highlighted job dissatisfaction, lack of career development and poor work-life balance as the main determinants of intention to leave,, which the researchers suggested can ‘help governments and hospital administrators combat the trend’.
Laura Maniscalco, co-author of the study and research fellow at the University of Palermo (UNIPA), said: ‘Many doctors want to leave their current workplaces because of the management and personal issues. In the high-stress environment of a hospital, they can face challenges in terms of work-life balance or conflicts that can result in bullying.
‘Additionally, the ineffectiveness of the management system and understaffing can force them to work in areas outside of their expertise, leading to role conflicts and reducing opportunities for career advancement.”
Domenica Matranga, a professor at the UNIPA and co-author of the study, added: ‘Our research suggests that nurses may [also] no longer find their job rewarding or valued. This issue is connected with relatively low salaries, tough working conditions and, of course, the physical and emotional pressure caused by the pandemic.‘
This latest study adds to ongoing research highlighting and addressing the pressures on clinical workforces across the EU and UK.
Recommendations to enhance the wellbeing of doctors in Europe were published in November 2023 as part of a new policy from the Standing Committee of European Doctors. These aimed to improve patient care, professional excellence and overall job satisfaction and included focusing on adequate staffing and workload management, embracing a people-focused working culture, championing mentoring and peer support networks and supporting doctors as parents and carers.
Staff retention and mental health issues have also been noted amongst UK clinicians in recent months. A survey of 1,958 NHS health professionals from across the UK in September highlighted understaffing as a main factor pushing healthcare workers to leave the NHS.
A UK surgical workforce census report published in January 2024 found that 61% of respondents cited burnout and stress as the main challenge in surgery due to excessive workloads, and 50% of respondents across all career grades indicated that they considered leaving the workforce in the past year.
And last summer NHS chief executive Amanda Pritchard acknowledged that the NHS was seeing higher levels of sickness among staff compared to pre-pandemic, particularly due to poor mental health and anxiety, some of which she said was ‘directly related to what people have been through over what was an extraordinarily difficult few years’.
The turnover crisis comes as the healthcare sector struggles with an existing shortage of medical personnel. Projections from the World Health Organization indicate that in six years Europe will need 18.2 million healthcare workers to meet the growing demand for healthcare services driven by an ageing population and increased prevalence of chronic diseases.
As a result, the authors of this latest METEOR Project study are urging healthcare managers across the EU to ‘devise effective retention strategies, taking into account job satisfaction, work engagement, and a positive working climate’, adding that ‘such internal policies are crucial, given the difficulty of finding replacements for departing professionals’.
26th February 2024
An e-health programme developed by the Cardiology Centres Netherlands (CCN) has been rolled out to patients at Amsterdam UMC’s Heart Centre to supplement their care and support cardiologists.
The HartWacht mobile app (HeartGuard, in English) is suitable for patients with high blood pressure, cardiac arrhythmias or heart failure and uses a small measurement instrument, around the size of a cereal bar, to monitor their blood pressure and arrythmias at home.
Making it possible to take an ECG remotely, the app means patients need to visit their cardiologist less frequently. It also gives clinicians more precise measurements and enables them to act faster where necessary.
Amsterdam UMC is the first academic hospital to use this e-health programme, which was developed in 2016 by CCN where it is already being used to track data from more than 3,000 patients.
Michiel Winter, cardiologist at Amsterdam UMC, leader of the HartWacht project, and chairman of CCN’s Board of Directors, said: ‘Since we started the e-health programme we have seen a decrease in the number of ambulance-calls for these patients, and, because we can see what is going on with the patient from a distance, we can immediately reassure and advise or intervene where necessary.’
In addition, CCN analyses show the system results in fewer visits to the emergency department, and that patients who use HartWacht come to the outpatient clinic less often and need fewer nursing days.
Dr Winter said home monitoring with the e-health tool offers peace of mind for patients who often have to deal with lifelong heart disease. ‘It is very reassuring for patients [as] they immediately receive feedback in the app after a measurement,’ he added.
Clinicians can also help patients in a timelier manner with less unnecessary care, as all patient data collected by the app is analysed by a central team before any abnormal readings are shared with the patient’s cardiologist.
Jasper Selder, cardiologist and biomedical engineer at Amsterdam UMC and co-leader of the e-health project, said: ‘It relieves us of our worries because all non-abnormal health measurements are filtered out – often the bulk of all measurements – so that we can focus on patients with abnormal measurements.
‘As a cardiologist, instead of having to look at dozens of heart rhythm and blood pressure measurements during the – often busy – outpatient check-ups, we now receive an immediate notification if one of those measurements falls outside the expected range, so there is more time for the cardiologist to focus on patient care.
‘Deviations also come to light more quickly and not only during checks. Based on the abnormality detected, we can immediately determine whether action is needed, such as adjusting medication or an extra check-up.’
According to Amsterdam UMC, further applications for diabetes and cardiovascular risk management will be added to the e-health programme this year.
16th February 2024
A new international project aiming to use artificial intelligence (AI) and genomics data to personalise therapies for patients with cardiovascular disease (CVD) has been announced.
The Next Generation Tools for Genome-Centric Multimodal Data Integration in Personalised Cardiovascular Medicine (NextGen) project aims to build AI-supported novel and synergistic tools to enable portable multimodal, multiomic and clinically oriented research in high-impact areas of cardiovascular medicine.
The tools will benefit researchers, innovators and healthcare professionals by identifying and overcoming health data linkage barriers in exemplar cardiovascular use cases that are complex or intractable with existing technology.
The ultimate goal is to provide faster diagnosis and better, more personalised treatments for patients while capitalising on increasing innovations and trends in AI technology.
The NextGen project will be delivered by a 21-member consortium of academic, clinical, technical and commercial partners from across Europe and the US, including the European Society for Cardiology, and led by University Medical Center (UMC) Utrecht and Queen Mary University of London.
Project coordinator Professor Pim van der Harst, interventional cardiologist and head of the department of cardiology at the UMC Utrecht, said: ‘No two people are exactly the same, and so it makes sense that each person needs a slightly different strategy to optimise their health. Personalised medicine is, therefore, the way forward for preventing heart disease, speeding up diagnosis, and monitoring and treating people with CVD.
‘To develop individualised therapies, we need to compile as much information as possible about individuals, and that’s where NextGen comes in. The unique picture we generate will then form the basis for improving cardiovascular health and wellbeing.’
Several real-world pilots will demonstrate the effectiveness of NextGen tools and will be integrated in the NextGen Pathfinder network of five collaborating clinical sites as a self-contained data ecosystem and comprehensive proof of concept.
The work will complement the ‘1+ Million Genomes’ initiative, which aims to enable secure access to genomics and clinical data across Europe, and the European Health Data Space – a European Commission governance framework for the safe and secure exchange, use and reuse of health data.
Consortium member Professor Panos Deloukas, professor of cardiovascular genomics and dean for Life Sciences at Queen Mary University of London’s William Harvey Research Institute, added: ‘This is a tremendous opportunity and a challenge we have in building the right toolbox that will allow [us] to unite CVD patient data across Europe and implement precision medicine to improve cardiovascular healthcare.’
The NextGen project has received €7.6 million from the EU’s Horizon Europe programme.
In August 2023, a genetic study revealed how the use of clopidogrel in British patients of south Asian ancestry appears to be less effective at preventing recurrent myocardial infarction than in those of European descent.
And earlier in 2023, single cell and spatial genomics combined with computational techniques were used to develop a comprehensive Heart Cell Atlas to better understand the heart and how it responds to treatments.
23rd January 2024
European doctors’ ambitions to keep building a ‘coherent’ and ‘equitable’ European Health Union have been published by the Standing Committee of European Doctors (CPME).
It’s ‘Health Check for Europe 2024-2029’ sets out a vision for the EU’s health priorities ahead of the upcoming European Parliament election in June.
This includes five ambitions urging European policy makers to tackle the health workforce crisis, ensure a safe digital transformation of healthcare, enable healthier living, guarantee accessibility and effectiveness of medicines and take climate action for better health.
Commenting on the ambitions outlined in the Health Check vision, CPME president Dr Christiaan Keijzer said: ‘Whilst European countries have made huge advances in collaboration on health in recent years, we cannot take a step backwards.
‘The Covid-19 pandemic has shown that health is the foundation of our economy and society, and exposed that problems that have not been solved. Our health systems still suffer from deep structural flaws and our health workforce is exhausted and undervalued.
‘The European Health Union is not complete: the EU needs a coherent long-term vision for health in Europe and beyond for equitable access to healthcare for patients.
‘European doctors remain strongly committed partners in making these ambitions a reality.‘
On the subject of recruitment and retention, the Health Check highlights issues of ‘untenable working conditions, excessive hours, and insufficient resources‘, which mean ‘medicine is losing its attractiveness as a life-long profession, and if we continue in this path we will not have a functioning health workforce.’
This follows the publication of CPME‘s policy in November 2023 providing recommendations to enhance the wellbeing of doctors across Europe.
The policy aims to improve patient care, professional excellence, and overall job satisfaction by addressing challenges such as work-related stress, organisational culture, supportive working environments, burnout and work-life balance.
The CPME presented the five ambitions to the president of the European Parliament, MEP Roberta Metsola on 22 January 2024.
12th January 2024
The subcutaneous drug foslevodopa-foscarbidopa (brand name Produodopa) has been launched in the European Union (EU) for the treatment of advanced Parkinson’s disease, its manufacturer AbbVie has announced.
It becomes the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy available in the EU for the treatment severe motor fluctuations and hyperkinesia (excessive movement) or dyskinesia (involuntary movement) in people living with advanced Parkinson’s disease and whose symptoms are inadequately controlled by other therapies.
The continuous delivery of foslevodopa-foscarbidopa provides levodopa 24-hours a day, which AbbVie said may help patients by extending the period when symptoms are well-controlled – often referred to as ‘On’ time.
‘On’ time signifies when symptoms are controlled, whereas ‘Off’ time occurs when symptoms return between medication doses.
Foslevodopa-foscarbidopa gained marketing authorisation through the European Medicine’s Agency’s decentralised procedure in the third quarter of 2022. The Vyafuser pump for the drug’s subcutaneous delivery received Conformité Européenne (CE) Mark in November of 2023.
Angelo Antonini, professor of neurology at the Department of Neuroscience, University of Padua, Italy, said: ‘This approval represents a significant advancement for those with Parkinson’s disease who have historically had limited treatment options for advanced stages.
‘When oral treatment no longer sufficiently helps with improvement in motor fluctuations, patients need alternative options. Produodopa’s around-the-clock infusion allows for continuous delivery of levodopa, the gold standard of treatment.’
The launch was supported by three studies, including the Phase 3, 12-month open-label M15-741 study in which the primary endpoint was to evaluate the safety and tolerability of foslevodopa-foscarbidopa.
Secondary endpoints included changes from baseline in normalised ‘Off’ and ‘On’ time, the percentage of patients reporting morning akinesia – defined as ‘Off’ time upon waking – and total scores from quality-of-life surveys.
Eligible patients included adults 30 years or older diagnosed with levodopa-responsive idiopathic Parkinson’s disease experiencing an average of greater than or equal to 2.5 hours of ‘Off’ time per day, as assessed by patient’s Parkinson’s disease diaries.
The results, published in the Journal of Neurology & Therapy, observed a reduction in motor fluctuations as early as Week 1 and persisted through Week 52, and the percentage of patients experiencing morning akinesia dropped from 77.7% at baseline to 27.8% at week 52.
The researchers concluded that there was a favourable benefit/risk profile and sustained improvements in ‘Off’ time and ‘On’ time without dyskinesia, and morning akinesia as measured by the percentage of patients in early morning ‘Off’ time.
The 12-week Phase 3 M15-736 study and a Phase 1 pharmacokinetic comparability study also supported the launch.
The majority of adverse events (AEs) with foslevodopa-foscarbidopa were non-serious and mild or moderate in severity. The most frequent AEs (greater than or equal to 10%) were infusion site events (infusion site erythema, infusion site cellulitis, infusion site nodule, infusion site pain, infusion site oedema, infusion site reaction, and infusion site infection), hallucination, fall, and anxiety.
Foslevodopa-foscarbidopa was recommended by the UK’s National Institute of Health and Care Excellence in autumn 2023 for treating advanced Parkinson’s with motor symptoms and the final technology appraisal guidance was published on 29 November 2023.
9th January 2024
Health inequalities saw more than one million people living in 90% of areas in England living shorter lives than they should have between 2011 and the start of the Covid-19 pandemic – equivalent to the whole population of Birmingham, or that of Edinburgh and Glasgow combined, new research has found.
According to research led by University College London’s Institute of Health Equity (IHE), the period from 2011 to 2019 saw more than a million people dying earlier than they otherwise would have done had they experienced the death rates seen in the least deprived decile of areas.
Of these excess deaths, 148,000 were additional to what might have been expected based on levels in the two years prior to 2011, the report – titled ’Health Inequalities, Lives Cut Short’ – said.
And in 2020, the level of excess deaths rose by an additional 28,000 compared to those over the previous five years.
To contextualise the UK’s downwards health trend, the IHE analysed European Union data and compared healthy life years (HLY) – the number of years a person is expected to continue to live in a healthy condition, and also called disability-free life expectancy – in the UK to other European Union countries.
In 2014, both males and females in the UK had a higher average number of healthy years lived (HYL) than those in the EU. However, by 2017, HLY in the UK had stagnated for men, and fallen for women.
In the same period, HLY increased by more than two years in the EU. Consequently, 10 EU countries had higher HLY than the UK for males, and 14 had higher HLY than the UK for females.
UCL IHE Director, Professor Sir Michael Marmot, said: ’If you needed a case study example of what not to do to reduce health inequalities, the UK provides it. The only other developed country doing worse is the USA, where life expectancy is falling.
’Our country has become poor and unhealthy, where a few rich, healthy people live. People care about their health, but it is deteriorating, with their lives shortening, through no fault of their own. Political leaders can choose to prioritise everyone’s health, or not. Currently they are not.’
Referring to this ’dismal state of affairs’, he is calling on political party leaders and MPs to prioritise health equity and wellbeing.
’Important as is the NHS – publicly funded and free at the point of use – action is needed on the social determinants of health: the conditions in which people are born, grow, live, work and age. These social conditions are the main cases of health inequalities,’ he said.
Ahead of the general election, the IHE is also proposing the appointment of an independent health equity commissioner and the establishment of a new cabinet-level health equity and wellbeing cross-departmental committee.
In 2020, Sir Michael’s ’Build Back Fairer: The Covid-19 Marmot Review’ document highlighted how pre-pandemic social and economic conditions contributed to the unequal Covid-19 death toll.
The UK cabinet office cited the report as ‘the most comprehensive early assessment of how Covid-19 exacerbated existing health inequalities’ when he was named in the 2023 King’s New Year Honours.
Last January, Sir Michael criticised the UK Government’s short-term policies being announced and rolled out, stating that they damage the service overall, and warning health leaders to be ‘aware of short-term fixes that might undermine a longer term agenda’ for the service.
18th September 2023
A translation function has been added to the Hospital Healthcare Europe website, meaning users can now read all content in their choice of English, French, German, Italian or Spanish.
In broadening access to content in this way, hospital managers and departmental heads across Europe can more easily stay up to date with innovative developments in healthcare to support their practice.
Users can select their language from the dropdown menu in the top right-hand corner of the site to access the latest news, reviews, interviews, case studies and more in their native, or chosen, language.
The launch of the translation function follows other recent developments to the Hospital Healthcare Europe website such as the introduction of a web browser notification system and and in-app notifications on iOS and Android to alert users when new content is published.
Further upgrades will be introduced over the coming weeks and months to provide a more comprehensive and streamlined user experience.
Download Hospital Healthcare Europe free app
© Cogora 2024
Cogora Limited. 1 Giltspur Street, London EC1A 9DD
Registered in the United Kingdom. Reg. No. 2147432
